SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Drugs reports Profit after tax of Rs 502.40 Mln, in the March 2021 quarter

15 May 2021 Evaluate
The revenue for the March 2021 quarter is pegged at Rs. 4520.80 millions, about 11.19% up against Rs. 4065.70 millions recorded during the year-ago period.The Net proft of the company remain more or less same to Rs. 502.40  millions from Rs. 565.60 millions ,decline by -11.17%.Operating Profit saw a handsome growth to 792.40 millions from 682.20 millions in the quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 4520.80 4065.70 11.19 19148.90 16349.20 17.12 19148.90 16349.20 17.12
Other Income 8.50 6.20 37.10 64.20 10.60 505.66 64.20 10.60 505.66
PBIDT 792.40 682.20 16.15 4076.90 2454.60 66.09 4076.90 2454.60 66.09
Interest 43.40 72.40 -40.06 226.10 322.00 -29.78 226.10 322.00 -29.78
PBDT 749.00 693.60 7.99 3853.00 2216.40 73.84 3853.00 2216.40 73.84
Depreciation 116.60 119.90 -2.75 476.00 466.70 1.99 476.00 466.70 1.99
PBT 632.40 573.70 10.23 3377.00 1749.70 93.00 3377.00 1749.70 93.00
TAX 130.00 8.10 1504.94 800.00 393.00 103.56 800.00 393.00 103.56
Deferred Tax -20.00 -155.00 -87.10 -45.00 -102.50 -56.10 -45.00 -102.50 -56.10
PAT 502.40 565.60 -11.17 2577.00 1356.70 89.95 2577.00 1356.70 89.95
Equity 932.00 233.00 300.00 932.00 233.00 300.00 932.00 233.00 300.00
PBIDTM(%) 17.53 16.78 4.46 21.29 15.01 41.81 21.29 15.01 41.81

Aarti Drugs Share Price

396.40 0.65 (0.16%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: